Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-HFrEF: Beta-blocker and Early Add-on Therapy with Ivabradine in Acute Heart Failure with Reduced Ejection Fraction
KCT0012126Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ivabradine and carvedilol in heart failure with reduced ejection fraction (HFrEF) and Acute Heart Failure (AHF), sponsored by Daewoong Pharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ivabradinecarvedilol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on KCT0012126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012126.